AdultPediatricDosage Forms & Strengths topical gel 10%; supplied as 100mg/1g unit (1.14mL) sachet Overactive Bladder Indicated for treatment of overactive bladder with symptoms of urge incontinence, frequency, and urgency Gel sachet (10%): Apply 100 mg (content of 1 sachet 10%) qDay Administration For topical application only; should not be ingested Apply to dry, intact skin on abdomen, upper arms/shoulders, or thigh Wash hands immediately after application; cover application site with clothing after gel has dried if direct skin-to-skin contact is anticipated Avoid showering for 1 hr following application Rotate application sites, avoid same site on consecutive daysSafety and efficacy not establishedInteraction CheckerEnter a drug name and oxybutynin topicalNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (3)lonafarniboxybutynin topical will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.pramlintidepramlintide, oxybutynin topical. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.secretinoxybutynin topical decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.Monitor Closely (100)abobotulinumtoxinAabobotulinumtoxinA increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumoxybutynin topical and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.amantadineoxybutynin topical, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.amitriptylineoxybutynin topical and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapineoxybutynin topical and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.aripiprazoleoxybutynin topical decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atracuriumatracurium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineatropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMatropine IV/IM and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.avapritiniboxybutynin topical will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.axitiniboxybutynin topical increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.belladonna alkaloidsbelladonna alkaloids and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumbelladonna and opium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.benperidoloxybutynin topical decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.benperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropinebenztropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholbethanechol increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbacholcarbachol increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.cevimelinecevimeline increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazineoxybutynin topical decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cisatracuriumcisatracurium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramineoxybutynin topical and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clozapineoxybutynin topical decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.clozapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclizinecyclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.darifenacindarifenacin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramineoxybutynin topical and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.dicyclominedicyclomine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydraminediphenhydramine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.donepezildonepezil increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, oxybutynin topical. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinoxybutynin topical and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinoxybutynin topical and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.droperidoloxybutynin topical decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.droperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.echothiophate iodideechothiophate iodide increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.fesoterodinefesoterodine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.finerenoneoxybutynin topical will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.flavoxateflavoxate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.fluphenazineoxybutynin topical decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.fluphenazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.galantaminegalantamine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.glycopyrrolateglycopyrrolate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.haloperidoloxybutynin topical decreases effects of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.oxybutynin topical decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.haloperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.henbanehenbane and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hyoscyaminehyoscyamine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneoxybutynin topical decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.iloperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.imipramineoxybutynin topical and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ipratropiumipratropium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isavuconazonium sulfateoxybutynin topical will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ivacaftoroxybutynin topical increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .lofepramineoxybutynin topical and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.lomitapideoxybutynin topical increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.loxapineoxybutynin topical decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledloxapine inhaled increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.oxybutynin topical decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.maprotilineoxybutynin topical and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.meclizinemeclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.methscopolaminemethscopolamine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.metoclopramideoxybutynin topical decreases effects of metoclopramide by pharmacodynamic antagonism. Use Caution/Monitor. May antagonize prokinetic effects.neostigmineneostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nitrofurantoinoxybutynin topical increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.nortriptylineoxybutynin topical and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.olanzapineoxybutynin topical decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.onabotulinumtoxinAonabotulinumtoxinA and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrineoxybutynin topical and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutyninoxybutynin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.paliperidoneoxybutynin topical decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.paliperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pancuroniumoxybutynin topical and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.perphenazineoxybutynin topical decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.perphenazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.physostigminephysostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pilocarpinepilocarpine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pimozideoxybutynin topical decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.pimozide increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pralidoximeoxybutynin topical and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.prochlorperazineoxybutynin topical decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.promethazineoxybutynin topical decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.promethazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.propanthelineoxybutynin topical and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.protriptylineoxybutynin topical and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.pyridostigminepyridostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.quetiapineoxybutynin topical decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.quetiapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rapacuroniumoxybutynin topical and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.risperidoneoxybutynin topical decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rocuroniumoxybutynin topical and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.scopolamineoxybutynin topical and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacinoxybutynin topical and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.succinylcholinesuccinylcholine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.thioridazineoxybutynin topical decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.thioridazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.thiothixeneoxybutynin topical decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.thiothixene increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tinidazoleoxybutynin topical will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.tiotropiumoxybutynin topical and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.tolterodineoxybutynin topical and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.trazodoneoxybutynin topical and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.trifluoperazineoxybutynin topical decreases levels of trifluoperazine by inhibition of